Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
Objective [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evalu...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2024-10-01
|
| Series: | Indian Journal of Radiology and Imaging |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1779634 |
| _version_ | 1827107428997529600 |
|---|---|
| author | Dheeratama Siripongsatian Attapon Jantarato Chetsadaporn Promteangtrong Anchisa Kunawudhi Peerapon Kiatkittikul Natphimol Boonkawin Sukanya Yaset Sirinsuda Somboon Chanisa Chotipanich |
| author_facet | Dheeratama Siripongsatian Attapon Jantarato Chetsadaporn Promteangtrong Anchisa Kunawudhi Peerapon Kiatkittikul Natphimol Boonkawin Sukanya Yaset Sirinsuda Somboon Chanisa Chotipanich |
| author_sort | Dheeratama Siripongsatian |
| collection | DOAJ |
| description |
Objective [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evaluated pretherapeutic PSMA PET-derived parameters to predict prostate-specific antigen (PSA) response in patients undergoing [177Lu]Lu-PSMA-617 RLT. |
| first_indexed | 2024-03-07T22:02:39Z |
| format | Article |
| id | doaj.art-cfbdec4d3c9e4966b21c1811fc8c80f4 |
| institution | Directory Open Access Journal |
| issn | 0971-3026 1998-3808 |
| language | English |
| last_indexed | 2025-03-20T10:10:28Z |
| publishDate | 2024-10-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Radiology and Imaging |
| spelling | doaj.art-cfbdec4d3c9e4966b21c1811fc8c80f42024-09-23T22:31:09ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Radiology and Imaging0971-30261998-38082024-10-01340457958710.1055/s-0044-1779634Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand TherapyDheeratama Siripongsatian0https://orcid.org/0000-0001-7914-7141Attapon Jantarato1Chetsadaporn Promteangtrong2Anchisa Kunawudhi3Peerapon Kiatkittikul4Natphimol Boonkawin5Sukanya Yaset6Sirinsuda Somboon7Chanisa Chotipanich8National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, ThailandNational Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand Objective [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evaluated pretherapeutic PSMA PET-derived parameters to predict prostate-specific antigen (PSA) response in patients undergoing [177Lu]Lu-PSMA-617 RLT.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1779634pretherapeutic PSMA PETmetastatic castration-resistant prostate cancerliver metastasis[177Lu]Lu-PSMA-617radioligand therapy |
| spellingShingle | Dheeratama Siripongsatian Attapon Jantarato Chetsadaporn Promteangtrong Anchisa Kunawudhi Peerapon Kiatkittikul Natphimol Boonkawin Sukanya Yaset Sirinsuda Somboon Chanisa Chotipanich Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy Indian Journal of Radiology and Imaging pretherapeutic PSMA PET metastatic castration-resistant prostate cancer liver metastasis [177Lu]Lu-PSMA-617 radioligand therapy |
| title | Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy |
| title_full | Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy |
| title_fullStr | Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy |
| title_full_unstemmed | Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy |
| title_short | Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy |
| title_sort | pretherapeutic psma pet derived semiquantitative parameters as predictors of psa response in patients with mcrpc receiving sup 177 sup lu lu psma 617 radioligand therapy |
| topic | pretherapeutic PSMA PET metastatic castration-resistant prostate cancer liver metastasis [177Lu]Lu-PSMA-617 radioligand therapy |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1779634 |
| work_keys_str_mv | AT dheeratamasiripongsatian pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT attaponjantarato pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT chetsadapornpromteangtrong pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT anchisakunawudhi pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT peeraponkiatkittikul pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT natphimolboonkawin pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT sukanyayaset pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT sirinsudasomboon pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy AT chanisachotipanich pretherapeuticpsmapetderivedsemiquantitativeparametersaspredictorsofpsaresponseinpatientswithmcrpcreceivingsup177suplulupsma617radioligandtherapy |